Amarin raises $70m in placing
Dublin-based venture capital company Fountain Healthcare was one of the lead investors in the placement which will enable Amarin to proceed with clinical trials of its drugs in development over the next three years.
Following the closing of the financing, chairman and chief executive officer of Amarin, Thomas Lynch, has decided he will step down as chief executive and will continue as chairman. Dr Declan Doogan, Amarin’s head of research and development, has agreed to assume the role of interim chief executive.
